KNSA

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 52.00 USD with a low forecast of 44.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kiniksa Pharmaceuticals International PLC revenue for the last quarter amounts to 180.86M USD, increased 61.17 % YoY.

Kiniksa Pharmaceuticals International PLC. EPS for the last quarter amounts to 0.23 USD, decreased -227.78 % YoY.

Kiniksa Pharmaceuticals International PLC (KNSA) has 315 emplpoyees as of December 16 2025.

Today KNSA has the market capitalization of 3.15B USD.